The O22 trial's positive result for adjuvant Pembrolizumab plus Belzutafan was unexpected, as experts believed kidney cancer recurrence was primarily immune-driven, not HIF-driven. This outcome forces a re-evaluation of the underlying biology of recurrence and suggests a significant role for HIF inhibition in the adjuvant setting.

Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

Subgroup analysis from LITESPARK 011 revealed a significantly stronger benefit (hazard ratio 0.47) for the Belzutifan combination in favorable-risk patients. This supports the hypothesis that these tumors are more purely dependent on the HIF/VEGF pathway, suggesting an angiogenic signature could emerge as a predictive biomarker for Belzutifan's efficacy.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

The RECITE trial proved romiplostim effectively maintains platelet counts, allowing patients to receive their full, intended chemotherapy dose (relative dose intensity). However, the critical link between maintaining this dose and actually improving progression-free or overall survival has not yet been established.

Chemotherapy is known to worsen metabolic parameters, but this should be viewed as an opportunity, not just a side effect. By actively correcting this metabolic dysfunction with adjunctive therapies, clinicians may be able to enhance the overall life-saving benefit of the chemotherapy itself.

Anemia is an on-target, expected side effect of the HIF2-alpha inhibitor belzutafan. Experienced clinicians proactively manage this by starting erythropoietin-stimulating agents (ESAs) when hemoglobin falls below 9 g/dL, and sometimes place the order preemptively to avoid treatment delays.

Despite both targeting angiogenesis, HIF inhibitors like belzutafan show different clinical activity. Belzutafan's success in an adjuvant trial, a setting where multiple VEGF TKIs failed, alongside its additive effect in combination therapies, demonstrates it engages a separate biological pathway.